# Pulmatrix, Inc.: financial statements, quarterly

PULM · Nasdaq · CIK 1574235 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pulm.md) · [Financials](/companies/pulm/financials.md) · [Filings](/companies/pulm/filings.md) · [Insiders](/companies/pulm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pulm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,753](/filings/0001493152-24-044163.md) | [2,202 d](/filings/0001493152-25-011084.md) | [5,885](/filings/0001641172-25-010533.md) | [1,552](/filings/0001641172-25-022357.md) | [366](/filings/0001493152-25-018256.md) | [3.0 d](/filings/0001493152-26-028902.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [3,963](/filings/0001493152-24-044163.md) | [3,516 d](/filings/0001493152-25-011084.md) | [3,512](/filings/0001641172-25-010533.md) | [2,834](/filings/0001641172-25-022357.md) | [814](/filings/0001493152-25-018256.md) | [6.0 d](/filings/0001493152-26-028902.md) | [19.0](/filings/0001493152-26-023368.md) | [14.0](/filings/0001493152-26-037594.md) | [8.0](/filings/0001493152-25-018256.md) | [(3.0) d](/filings/0001493152-26-028902.md) | [3.0](/filings/0001493152-26-023368.md) | [2.0](/filings/0001493152-26-037594.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,939)](/filings/0001493152-24-044163.md) | [(2,225) d](/filings/0001493152-25-011084.md) | [747](/filings/0001641172-25-010533.md) | [(5,901)](/filings/0001641172-25-022357.md) | [(2,657)](/filings/0001493152-25-018256.md) | [(1,952) d](/filings/0001493152-26-028902.md) | [(1,847)](/filings/0001493152-26-023368.md) | [(1,548)](/filings/0001493152-26-037594.md) | [(866)](/filings/0001493152-25-018256.md) | [(908) d](/filings/0001493152-26-028902.md) | [(1,292)](/filings/0001493152-26-023368.md) | [(1,046)](/filings/0001493152-26-037594.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001493152-24-044163.md) | not reported | [0.0](/filings/0001641172-25-010533.md) | [0.0](/filings/0001641172-25-022357.md) | [0.0](/filings/0001493152-25-018256.md) | not reported | [0.0](/filings/0001641172-25-010533.md) | [0.0](/filings/0001641172-25-022357.md) | [0.0](/filings/0001493152-25-018256.md) | [0.0 d](/filings/0001493152-26-028902.md) | not reported | not reported |
| Net income | $k | [(3,774)](/filings/0001493152-24-044163.md) | [(2,083) d](/filings/0001493152-25-011084.md) | [825](/filings/0001493152-25-018256.md) | [(5,811)](/filings/0001493152-25-018256.md) | [(2,587)](/filings/0001493152-25-018256.md) | [(1,986) d](/filings/0001493152-26-028902.md) | [(1,808)](/filings/0001493152-26-037594.md) | [(1,549)](/filings/0001493152-26-037594.md) | [(877)](/filings/0001493152-25-018256.md) | [(928) d](/filings/0001493152-26-028902.md) | [(1,172)](/filings/0001493152-26-037594.md) | [(1,036)](/filings/0001493152-26-037594.md) |
| Diluted EPS | $ per share | [(1.03)](/filings/0001493152-24-044163.md) | not reported | [0.23](/filings/0001641172-25-010533.md) | [(1.59)](/filings/0001641172-25-022357.md) | [(0.71)](/filings/0001493152-25-018256.md) | not reported | [(0.50)](/filings/0001493152-26-023368.md) | [(0.42)](/filings/0001493152-26-037594.md) | [(0.24)](/filings/0001493152-25-018256.md) | not reported | [(0.32)](/filings/0001493152-26-023368.md) | [(0.29)](/filings/0001493152-26-037594.md) |
| Basic EPS | $ per share | [(1.03)](/filings/0001493152-24-044163.md) | not reported | [0.23](/filings/0001641172-25-010533.md) | [(1.59)](/filings/0001641172-25-022357.md) | [(0.71)](/filings/0001493152-25-018256.md) | not reported | [(0.50)](/filings/0001493152-26-023368.md) | [(0.42)](/filings/0001493152-26-037594.md) | [(0.24)](/filings/0001493152-25-018256.md) | not reported | [(0.32)](/filings/0001493152-26-023368.md) | [(0.29)](/filings/0001493152-26-037594.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.3](/filings/0001493152-24-044163.md) | [19.2](/filings/0001493152-25-011084.md) | [16.3](/filings/0001641172-25-010533.md) | [12.4](/filings/0001641172-25-022357.md) | [10.8](/filings/0001493152-25-018256.md) | [9.5](/filings/0001493152-26-028902.md) | [7.7](/filings/0001493152-26-023368.md) | [5.8](/filings/0001493152-26-037594.md) | [4.8](/filings/0001493152-25-018256.md) | [4.1](/filings/0001493152-26-037594.md) | [3.3](/filings/0001493152-26-023368.md) | [2.2](/filings/0001493152-26-037594.md) |
| Current assets | $m | [23.2](/filings/0001493152-23-040012.md) | [20.8](/filings/0001493152-25-011084.md) | [17.6](/filings/0001493152-24-018579.md) | [15.6](/filings/0001493152-24-031478.md) | [11.4](/filings/0001493152-24-044163.md) | [9.9](/filings/0001493152-26-028902.md) | [8.0](/filings/0001641172-25-010533.md) | [6.1](/filings/0001641172-25-022357.md) | [5.0](/filings/0001493152-25-018256.md) | [4.1](/filings/0001493152-26-037594.md) | [4.5](/filings/0001493152-26-023368.md) | [3.2](/filings/0001493152-26-037594.md) |
| Total assets | $m | [36.8](/filings/0001493152-23-040012.md) | [34.0](/filings/0001493152-25-011084.md) | [30.4](/filings/0001493152-24-018579.md) | [15.8](/filings/0001493152-24-031478.md) | [11.5](/filings/0001493152-24-044163.md) | [9.9](/filings/0001493152-26-028902.md) | [8.1](/filings/0001641172-25-010533.md) | [6.2](/filings/0001641172-25-022357.md) | [5.0](/filings/0001493152-25-018256.md) | [4.1](/filings/0001493152-26-037594.md) | [4.5](/filings/0001493152-26-023368.md) | [3.2](/filings/0001493152-26-037594.md) |
| Current liabilities | $m | [4.4](/filings/0001493152-23-040012.md) | [3.9](/filings/0001493152-25-011084.md) | [3.1](/filings/0001493152-24-018579.md) | [2.5](/filings/0001493152-24-031478.md) | [0.6](/filings/0001493152-24-044163.md) | [0.9](/filings/0001493152-26-028902.md) | [0.9](/filings/0001641172-25-010533.md) | [0.5](/filings/0001641172-25-022357.md) | [0.2](/filings/0001493152-25-018256.md) | [0.3](/filings/0001493152-26-037594.md) | [0.9](/filings/0001493152-26-023368.md) | [0.7](/filings/0001493152-26-037594.md) |
| Total liabilities | $m | [16.9](/filings/0001493152-23-040012.md) | [16.0](/filings/0001493152-25-011084.md) | [11.4](/filings/0001493152-24-018579.md) | [2.5](/filings/0001493152-24-031478.md) | [0.6](/filings/0001493152-24-044163.md) | [1.0](/filings/0001493152-26-028902.md) | [0.9](/filings/0001641172-25-010533.md) | [0.5](/filings/0001641172-25-022357.md) | [0.2](/filings/0001493152-25-018256.md) | [0.3](/filings/0001493152-26-037594.md) | [0.9](/filings/0001493152-26-023368.md) | [0.7](/filings/0001493152-26-037594.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [19.9](/filings/0001493152-24-044163.md) | [18.0](/filings/0001493152-26-028902.md) | [19.0](/filings/0001493152-25-018256.md) | [13.3](/filings/0001493152-25-018256.md) | [10.9](/filings/0001493152-25-018256.md) | [8.9](/filings/0001493152-26-037594.md) | [7.1](/filings/0001493152-26-037594.md) | [5.6](/filings/0001493152-26-037594.md) | [4.7](/filings/0001493152-25-018256.md) | [3.8](/filings/0001493152-26-037594.md) | [3.6](/filings/0001493152-26-037594.md) | [2.6](/filings/0001493152-26-037594.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,142) d](/filings/0001493152-24-044163.md) | [(2,011) d](/filings/0001493152-25-011084.md) | [(2,719)](/filings/0001641172-25-010533.md) | [(3,677) d](/filings/0001641172-25-022357.md) | [(3,059) d](/filings/0001493152-25-018256.md) | [(1,261) d](/filings/0001493152-26-028902.md) | [(1,813)](/filings/0001493152-26-023368.md) | [(1,883) d](/filings/0001493152-26-037594.md) | [(1,031) d](/filings/0001493152-25-018256.md) | [(706) d](/filings/0001493152-26-028902.md) | [(1,067)](/filings/0001493152-26-023368.md) | [(1,106) d](/filings/0001493152-26-037594.md) |
| Capital expenditure | $k | [313 d](/filings/0001493152-24-044163.md) | [305 d](/filings/0001493152-25-011084.md) | [154](/filings/0001641172-25-010533.md) | [244 d](/filings/0001641172-25-022357.md) | [0.0 d](/filings/0001493152-25-018256.md) | [0.0 d](/filings/0001493152-26-028902.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3,478](/filings/0001493152-23-040012.md) | [3.7](/filings/0001493152-24-018579.md) | [3.7](/filings/0001493152-24-031478.md) | [3.7](/filings/0001493152-24-044163.md) | [3.7](/filings/0001641172-25-010533.md) | [3.7](/filings/0001641172-25-022357.md) | [3.7](/filings/0001493152-25-018256.md) | [3.7](/filings/0001493152-26-023368.md) | [3.7](/filings/0001493152-26-037594.md) | [3.7](/filings/0001493152-25-018256.md) | [3.7](/filings/0001493152-26-023368.md) | [3.7](/filings/0001493152-26-037594.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,652,285 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037594.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.